title: Question regarding ziprasidone and QTc interval prolongation in the ZODIAC study.
authors.forename: W Victor R
authors.initials: WV
authors.lastname: Vieweg
authors.forename: Mehrul
authors.initials: M
authors.lastname: Hasnain
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced* / Q000401:mortality; D008297:Male; D010879:Piperazines / Q000009:adverse effects*; D012559:Schizophrenia / Q000188:drug therapy* / Q000401:mortality; D013844:Thiazoles / Q000009:adverse effects*; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D010879:Piperazines; D013844:Thiazoles; C092292:ziprasidone